vTv Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
vTv Therapeutics Q2 net loss widens on higher trial costs
Brief: VTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
vTv Therapeutics posts Q1 profit on license payment
vTv Therapeutics Q4 net loss widens on higher expenses
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet
U.S. STOCKS ON THE MOVE-Constellation Energy, Williams-Sonoma
U.S. STOCKS ON THE MOVE-Lowe's, TJX Companies, Target
U.S. STOCKS ON THE MOVE-DoorDash, gold and silver miners
BTIG turns bullish on biotech sector, sees 2026 as 'banner year'
U.S. RESEARCH ROUNDUP- Amgen, Crowdstrike, Micron Technology
vTv Therapeutics Q3 net loss widens to $8.7 mln
vTv Therapeutics Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: VTV Therapeutics Announces Reinitiation Of Screening In CATT1 Phase 3 Trial
vTv Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Directorate Change
U.S. STOCKS ON THE MOVE-Walmart, Ford Motor, Starbucks
U.S. STOCKS ON THE MOVE-Simply Good Foods, Microbot Medical, PacBio